董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Bill J. White | 男 | Independent Director | 65 | 19.88万美元 | 0.22 | 2026-04-27 |
| Christopher C. Schreiber | 男 | Independent Director | 60 | 25.71万美元 | 0.22 | 2026-04-27 |
| Joshua N. Silverman | 男 | Director and Executive Chairman | 55 | 67.52万美元 | 0.87 | 2026-04-27 |
| Mitchell Glass | 男 | Chief Medical Officer and Director | 74 | 39.21万美元 | 0.23 | 2026-04-27 |
| Stephen Friscia | 男 | Independent Director | 55 | 19.88万美元 | 0.22 | 2026-04-27 |
| Bruce Bernstein | 男 | Independent Director | 62 | 15.88万美元 | 0.0023 | 2026-04-27 |
| Chelsea Voss | 女 | Director | 32 | 未披露 | 未持股 | 2026-04-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Joshua N. Silverman | 男 | Director and Executive Chairman | 55 | 67.52万美元 | 0.87 | 2026-04-27 |
| Ian Rhodes | 男 | Interim Chief Financial Officer | 54 | 16.65万美元 | 未持股 | 2026-04-27 |
| Mitchell Glass | 男 | Chief Medical Officer and Director | 74 | 39.21万美元 | 0.23 | 2026-04-27 |
董事简历
中英对照 | 中文 | 英文- Bill J. White
-
BillJ.White自2017年8月8日起担任我们的董事。White先生在财务管理、运营和业务发展方面有着超过30年的经验。他目前担任Intellicheck Mobilisa，Inc.（一家在纽约证券交易所MKT上市的技术公司）的首席财务官、财务主管和秘书。任职Intellicheck Mobilisa公司之前，他曾担任FocusMicro公司的首席财务官、秘书和财务主管11年。作为FM的联合创始人，White先生在从公司成立到五年内年收入超过3600万美元的发展过程中发挥了不可或缺的作用。White先生拥有广泛的国内和国际经验，包括管理快速和显著的增长，进口/出口，实施艰难的成本管理举措，利用新的增长机会，并购，战略规划，资源分配，税收合规和组织发展。共同创立FM公司之前，他曾担任政府部门的多种财务领导职务15年。White先生的职业生涯始于公共会计。White先生拥有华盛顿州立大学（Washington State University）工商管理文学学士学位，是一名注册舞弊审查员。
Bill J. White has been Q/C Technologies, Inc. director since August 8, 2017. Mr. White has more than 30 years of experience in financial management, operations and business development. Most recently, he served as Chief Financial Officer of Sidus Space, Inc. (Nasdaq: SIDU), as the chief financial officer for ProPhase Labs Inc. (Nasdaq: PRPH), and the chief financial officer, chief operating officer, treasurer and secretary of Intellicheck, Inc., (Nasdaq: IDN). Prior to working at Intellicheck, Inc., he served 11 years as the chief financial officer, chief operating officer, secretary and treasurer of FocusMicro, Inc. ("FM"). As co founder of FM, Mr. White played an integral role in growing the business from the company's inception to leading its international expansion into Dubai, UAE. Mr. White has broad domestic and international experience including managing rapid and significant growth, import/export, implementing tough cost management initiatives, exploiting new growth opportunities, merger and acquisitions, strategic planning, resource allocation, tax compliance and organization development. Prior to co founding FM, he served 15 years in various financial leadership positions in the government sector. Mr. White started his career in Public Accounting. Mr. White holds a Bachelor of Arts in Business Administration from Washington State University and is a Certified Fraud Examiner. - BillJ.White自2017年8月8日起担任我们的董事。White先生在财务管理、运营和业务发展方面有着超过30年的经验。他目前担任Intellicheck Mobilisa，Inc.（一家在纽约证券交易所MKT上市的技术公司）的首席财务官、财务主管和秘书。任职Intellicheck Mobilisa公司之前，他曾担任FocusMicro公司的首席财务官、秘书和财务主管11年。作为FM的联合创始人，White先生在从公司成立到五年内年收入超过3600万美元的发展过程中发挥了不可或缺的作用。White先生拥有广泛的国内和国际经验，包括管理快速和显著的增长，进口/出口，实施艰难的成本管理举措，利用新的增长机会，并购，战略规划，资源分配，税收合规和组织发展。共同创立FM公司之前，他曾担任政府部门的多种财务领导职务15年。White先生的职业生涯始于公共会计。White先生拥有华盛顿州立大学（Washington State University）工商管理文学学士学位，是一名注册舞弊审查员。
- Bill J. White has been Q/C Technologies, Inc. director since August 8, 2017. Mr. White has more than 30 years of experience in financial management, operations and business development. Most recently, he served as Chief Financial Officer of Sidus Space, Inc. (Nasdaq: SIDU), as the chief financial officer for ProPhase Labs Inc. (Nasdaq: PRPH), and the chief financial officer, chief operating officer, treasurer and secretary of Intellicheck, Inc., (Nasdaq: IDN). Prior to working at Intellicheck, Inc., he served 11 years as the chief financial officer, chief operating officer, secretary and treasurer of FocusMicro, Inc. ("FM"). As co founder of FM, Mr. White played an integral role in growing the business from the company's inception to leading its international expansion into Dubai, UAE. Mr. White has broad domestic and international experience including managing rapid and significant growth, import/export, implementing tough cost management initiatives, exploiting new growth opportunities, merger and acquisitions, strategic planning, resource allocation, tax compliance and organization development. Prior to co founding FM, he served 15 years in various financial leadership positions in the government sector. Mr. White started his career in Public Accounting. Mr. White holds a Bachelor of Arts in Business Administration from Washington State University and is a Certified Fraud Examiner.
- Christopher C. Schreiber
-
ChristopherC.Schreiber自2017年8月8日起担任我们的董事，目前担任我们的执行主席。Schreiber先生自2020年7月21日起担任我们的总裁。Schreiber先生结合了超过30年的证券行业经验。作为Taglich Brothers，Inc.的资本市场董事总经理，Schreiber先生建立在他在资本市场，交易结构和银团的广泛背景之上。任职Taglich Brothers，Inc.之前，他曾担任Paulson Investment Company（一个40年的全方位服务投资银行公司）的董事会成员。此外，Schreiber先生担任Long Island Express North的董事和合伙人，这是一家为团队和个人提供的精英曲棍球训练机构。他也是Fox Lane Youth Lacrosse（一个社区青年项目）的董事会志愿者。Schreiber先生毕业于约翰霍普金斯大学（Johns Hopkins University），在那里他获得了政治学学士学位。
Christopher C. Schreiber has been Q/C Technologies, Inc. director since August 8, 2017 and he previously served as Q/C Technologies, Inc. Chief Executive Officer, President, and Executive Chairman of the Board at various times. Mr. Schreiber combines over 30 years of experience in the securities industry. Mr. Schrieber retired in 2023 from his position as the Managing Director of Capital Markets at Taglich Brothers, Inc., where Mr. Schreiber built upon his extensive background in capital markets, deal structures, and syndications. Prior to his time at Taglich Brothers, Inc., he was a member of the board of directors of Paulson Investment Company, a 40 year old full service investment banking firm. In 2023, Mr. Schrieber joined the Board of Directors of Sonon Group, a German based company that focuses on providing solar powered mobility applications. In addition, Mr. Schreiber serves as a director and partner of Long Island Express North, an elite lacrosse training organization for teams and individuals. Mr. Schreiber is a graduate of Johns Hopkins University, where he received a bachelor's degree in political science. - ChristopherC.Schreiber自2017年8月8日起担任我们的董事，目前担任我们的执行主席。Schreiber先生自2020年7月21日起担任我们的总裁。Schreiber先生结合了超过30年的证券行业经验。作为Taglich Brothers，Inc.的资本市场董事总经理，Schreiber先生建立在他在资本市场，交易结构和银团的广泛背景之上。任职Taglich Brothers，Inc.之前，他曾担任Paulson Investment Company（一个40年的全方位服务投资银行公司）的董事会成员。此外，Schreiber先生担任Long Island Express North的董事和合伙人，这是一家为团队和个人提供的精英曲棍球训练机构。他也是Fox Lane Youth Lacrosse（一个社区青年项目）的董事会志愿者。Schreiber先生毕业于约翰霍普金斯大学（Johns Hopkins University），在那里他获得了政治学学士学位。
- Christopher C. Schreiber has been Q/C Technologies, Inc. director since August 8, 2017 and he previously served as Q/C Technologies, Inc. Chief Executive Officer, President, and Executive Chairman of the Board at various times. Mr. Schreiber combines over 30 years of experience in the securities industry. Mr. Schrieber retired in 2023 from his position as the Managing Director of Capital Markets at Taglich Brothers, Inc., where Mr. Schreiber built upon his extensive background in capital markets, deal structures, and syndications. Prior to his time at Taglich Brothers, Inc., he was a member of the board of directors of Paulson Investment Company, a 40 year old full service investment banking firm. In 2023, Mr. Schrieber joined the Board of Directors of Sonon Group, a German based company that focuses on providing solar powered mobility applications. In addition, Mr. Schreiber serves as a director and partner of Long Island Express North, an elite lacrosse training organization for teams and individuals. Mr. Schreiber is a graduate of Johns Hopkins University, where he received a bachelor's degree in political science.
- Joshua N. Silverman
-
Joshua N. Silverman，自2020年5月28日起担任Stablex Technologies，Inc.董事，目前担任Stablex Technologies，Inc.执行董事长兼首席执行官。在2023年12月13日被任命担任这些职位之前，Silverman先生曾担任董事会主席。在合并之前，Silverman先生自2018年合并（定义见下文）以来一直担任DropCar董事会成员。Silverman先生目前担任Parkfield Funding LLC的管理成员。Silverman先生是投资咨询公司Iroquois Capital Management，LLC（“Iroquois”）的联合创始人，之前是其负责人和管理合伙人。从2003年成立到2016年7月，Silverman先生担任Iroquois的联席首席投资官。在Iroquois任职期间，他设计并执行了复杂的交易，构建和谈判对公共和私营公司的投资，并经常被这类公司要求解决与公司结构、现金流和管理相关的低效率问题。2000年至2003年，Silverman先生担任商业银行Vertical Ventures，LLC的联席首席投资官。在组建Iroquois之前，Silverman先生是专门从事并购的精品咨询公司Joele Frank的董事。此前，Silverman曾担任美国总统助理新闻秘书。Silverman先生目前担任MYMD Pharmaceuticals，Inc.（NASDAQ：MYMD）、Pharmacyte，Inc.（NASDAQ：PMCB）、Synaptogenix, Inc.TERM3（NASDAQ：SNPX）和Petros Pharmaceutical，Inc.（NASDAQ：PTPI）的董事，这些公司均为上市公司。他此前于2014年7月至2016年8月担任国家控股公司董事，并于2016年8月至2018年10月担任Marker Therapeutics公司董事。Silverman先生于1992年获得了Lehigh大学的学士学位。
Joshua N. Silverman has served as a director of the Company since August 2022 and as Pharmacyte Biotech, Inc.'s Chief Executive Officer, President and Chairman of the Board since October 2022. Mr. Silverman has served as the managing member of Parkfield Funding LLC since August 2016. Mr. Silverman co founded Iroquois Capital Management, LLC ("Iroquois"), an investment advisory firm, in 2003 and served as its principal, managing partner and co chief investment officer until July 2016. While at Iroquois, he designed and executed complex transactions, structuring and negotiating investments in both public and private companies and has often been called upon by the companies solve inefficiencies as they relate to corporate structure, cash flow, and management. From 2000 to 2003, Mr. Silverman served as co chief investment officer of Vertical Ventures, LLC, a merchant bank. Prior to forming Iroquois, Mr. Silverman was a director of Joele Frank, a boutique consulting firm specializing in mergers and acquisitions. Previously, Mr. Silverman served as assistant press secretary to the president of the U.S. Mr. Silverman currently serves as an Executive Chairman of Fabric AI, Inc., (Nasdaq: FABC), Q/C Technologies, Inc. (Nasdaq: QCLS), TAO Synergies Inc. (Nasdaq: TAOX) and Petros Pharmaceutical, Inc. (OTC: PTPI). He previously served as a director of Protagenic Therapeutics, Inc. (Nasdaq: PTIX) from 2016 to 2022. Mr. Silverman received his B.A. from Lehigh University in 1992. - Joshua N. Silverman，自2020年5月28日起担任Stablex Technologies，Inc.董事，目前担任Stablex Technologies，Inc.执行董事长兼首席执行官。在2023年12月13日被任命担任这些职位之前，Silverman先生曾担任董事会主席。在合并之前，Silverman先生自2018年合并（定义见下文）以来一直担任DropCar董事会成员。Silverman先生目前担任Parkfield Funding LLC的管理成员。Silverman先生是投资咨询公司Iroquois Capital Management，LLC（“Iroquois”）的联合创始人，之前是其负责人和管理合伙人。从2003年成立到2016年7月，Silverman先生担任Iroquois的联席首席投资官。在Iroquois任职期间，他设计并执行了复杂的交易，构建和谈判对公共和私营公司的投资，并经常被这类公司要求解决与公司结构、现金流和管理相关的低效率问题。2000年至2003年，Silverman先生担任商业银行Vertical Ventures，LLC的联席首席投资官。在组建Iroquois之前，Silverman先生是专门从事并购的精品咨询公司Joele Frank的董事。此前，Silverman曾担任美国总统助理新闻秘书。Silverman先生目前担任MYMD Pharmaceuticals，Inc.（NASDAQ：MYMD）、Pharmacyte，Inc.（NASDAQ：PMCB）、Synaptogenix, Inc.TERM3（NASDAQ：SNPX）和Petros Pharmaceutical，Inc.（NASDAQ：PTPI）的董事，这些公司均为上市公司。他此前于2014年7月至2016年8月担任国家控股公司董事，并于2016年8月至2018年10月担任Marker Therapeutics公司董事。Silverman先生于1992年获得了Lehigh大学的学士学位。
- Joshua N. Silverman has served as a director of the Company since August 2022 and as Pharmacyte Biotech, Inc.'s Chief Executive Officer, President and Chairman of the Board since October 2022. Mr. Silverman has served as the managing member of Parkfield Funding LLC since August 2016. Mr. Silverman co founded Iroquois Capital Management, LLC ("Iroquois"), an investment advisory firm, in 2003 and served as its principal, managing partner and co chief investment officer until July 2016. While at Iroquois, he designed and executed complex transactions, structuring and negotiating investments in both public and private companies and has often been called upon by the companies solve inefficiencies as they relate to corporate structure, cash flow, and management. From 2000 to 2003, Mr. Silverman served as co chief investment officer of Vertical Ventures, LLC, a merchant bank. Prior to forming Iroquois, Mr. Silverman was a director of Joele Frank, a boutique consulting firm specializing in mergers and acquisitions. Previously, Mr. Silverman served as assistant press secretary to the president of the U.S. Mr. Silverman currently serves as an Executive Chairman of Fabric AI, Inc., (Nasdaq: FABC), Q/C Technologies, Inc. (Nasdaq: QCLS), TAO Synergies Inc. (Nasdaq: TAOX) and Petros Pharmaceutical, Inc. (OTC: PTPI). He previously served as a director of Protagenic Therapeutics, Inc. (Nasdaq: PTIX) from 2016 to 2022. Mr. Silverman received his B.A. from Lehigh University in 1992.
- Mitchell Glass
-
Mitchell Glass，自2024年4月8日起担任TNF Pharmaceuticals，Inc.董事，目前担任TNF Pharmaceuticals，Inc.总裁兼首席医疗官，该职位自2024年6月13日起担任。Glass博士是生命科学行业35年的资深人士。他的经历范围很广，从十大制药公司的高级职位到投资和管理初创企业和生物技术。在宾夕法尼亚大学从事了七年的研究、教学和患者护理工作后，Glass博士于1988年加入ICI Pharmaceuticals。他成立了肺部治疗小组，并领导了抗白三烯ACCOLATE 的开发和提交。从1995年到1996年，Dr. Glass担任SmithKline Beecham的副总裁兼董事，负责心血管、呼吸、肾脏和代谢药物的开发和商业化，包括提交COREG 的NDA/MAA。1998年至2003年，Glass博士担任AtheroGenics，Inc.（AGIX）首席医疗官兼临床开发和监管事务副总裁。他领导了AGI 1067从IND到3期的产品开发，是首次公开发行团队成员。Glass博士加入AQUMEN Biopharmaceuticals KK和NA，担任AQUMEN NA首席执行官和董事。自2008年以来，Glass博士一直担任OrphageniX Inc.（基因编辑）和AVATAR Biotechnologies（生物仿制药）的董事，现在是Invion LTD的研发执行副总裁和首席医疗官。Glass博士毕业于芝加哥大学，获得了内科、肺部和重症医学的董事会认证。
Mitchell Glass has been Q/C Technologies, Inc. director since April 8, 2024, and currently serves as Q/C Technologies, Inc. Chief Medical Officer, a position he has held since June 13, 2024. Dr. Glass previously served as President of the Company from June 13, 2024 until September 1, 2025. Dr. Glass is presently Chief Executive Officer of Chronic Airway Therapeutics, Chairman and Chief Executive Officer of ACCOLADE Pharma LLC and a principal at Broom Street Associates. Previously, Dr. Glass was director of pulmonary therapeutics at ICI/Zeneca and responsible world wide for the development of zafirlukast ("Accolate), the first successful antileukotriene for the treatment of asthma. Dr. Glass also served as Vice President at SmithKline Beecham beginning March, 1995, where he also held executive roles in the development of carvedilol (COREG) for heart failure, eprosartan (TEVETEN) for hypertension and led the worldwide portfolio development in cardiovascular, respiratory, renal and metabolic diseases and disorders. At Athrogenix, Dr. Glass led the development of AGI1067 to a successful end of phase 2 meeting with the FDA. After 2 years as the CSO of the University City Science Center in Philadelphia between 2005 and 2006, which included responsibility for 54 early stage companies, Dr. Glass joined Aqumen Pharma KK ("Aqumen Pharma") in 2006 as Director Aqumen KK. Dr. Glass also served as Chief Executive Officer and Chief Medical Officer of Aqumen Pharma's U.S. subsidiary was responsible for the ophthalmic portfolio, the lead compound of which was successfully developed and marketed in the U.S. and served in such roles until 2011. Previously, Dr. Glass served as the Chief Medical Officer and Director at Invion Plc. (ASX IVN) ("Invion") beginning 2011 until 2019 and led the de merger of Invion into Chronic Airway Therapeutics, the lead compound of which, nadolol, executed a positive proof of concept study in smokers with bronchitis. Dr. Glass graduated from the University of Chicago and is board certified in internal medicine, pulmonary and critical care medicine. - Mitchell Glass，自2024年4月8日起担任TNF Pharmaceuticals，Inc.董事，目前担任TNF Pharmaceuticals，Inc.总裁兼首席医疗官，该职位自2024年6月13日起担任。Glass博士是生命科学行业35年的资深人士。他的经历范围很广，从十大制药公司的高级职位到投资和管理初创企业和生物技术。在宾夕法尼亚大学从事了七年的研究、教学和患者护理工作后，Glass博士于1988年加入ICI Pharmaceuticals。他成立了肺部治疗小组，并领导了抗白三烯ACCOLATE 的开发和提交。从1995年到1996年，Dr. Glass担任SmithKline Beecham的副总裁兼董事，负责心血管、呼吸、肾脏和代谢药物的开发和商业化，包括提交COREG 的NDA/MAA。1998年至2003年，Glass博士担任AtheroGenics，Inc.（AGIX）首席医疗官兼临床开发和监管事务副总裁。他领导了AGI 1067从IND到3期的产品开发，是首次公开发行团队成员。Glass博士加入AQUMEN Biopharmaceuticals KK和NA，担任AQUMEN NA首席执行官和董事。自2008年以来，Glass博士一直担任OrphageniX Inc.（基因编辑）和AVATAR Biotechnologies（生物仿制药）的董事，现在是Invion LTD的研发执行副总裁和首席医疗官。Glass博士毕业于芝加哥大学，获得了内科、肺部和重症医学的董事会认证。
- Mitchell Glass has been Q/C Technologies, Inc. director since April 8, 2024, and currently serves as Q/C Technologies, Inc. Chief Medical Officer, a position he has held since June 13, 2024. Dr. Glass previously served as President of the Company from June 13, 2024 until September 1, 2025. Dr. Glass is presently Chief Executive Officer of Chronic Airway Therapeutics, Chairman and Chief Executive Officer of ACCOLADE Pharma LLC and a principal at Broom Street Associates. Previously, Dr. Glass was director of pulmonary therapeutics at ICI/Zeneca and responsible world wide for the development of zafirlukast ("Accolate), the first successful antileukotriene for the treatment of asthma. Dr. Glass also served as Vice President at SmithKline Beecham beginning March, 1995, where he also held executive roles in the development of carvedilol (COREG) for heart failure, eprosartan (TEVETEN) for hypertension and led the worldwide portfolio development in cardiovascular, respiratory, renal and metabolic diseases and disorders. At Athrogenix, Dr. Glass led the development of AGI1067 to a successful end of phase 2 meeting with the FDA. After 2 years as the CSO of the University City Science Center in Philadelphia between 2005 and 2006, which included responsibility for 54 early stage companies, Dr. Glass joined Aqumen Pharma KK ("Aqumen Pharma") in 2006 as Director Aqumen KK. Dr. Glass also served as Chief Executive Officer and Chief Medical Officer of Aqumen Pharma's U.S. subsidiary was responsible for the ophthalmic portfolio, the lead compound of which was successfully developed and marketed in the U.S. and served in such roles until 2011. Previously, Dr. Glass served as the Chief Medical Officer and Director at Invion Plc. (ASX IVN) ("Invion") beginning 2011 until 2019 and led the de merger of Invion into Chronic Airway Therapeutics, the lead compound of which, nadolol, executed a positive proof of concept study in smokers with bronchitis. Dr. Glass graduated from the University of Chicago and is board certified in internal medicine, pulmonary and critical care medicine.
- Stephen Friscia
-
Stephen Friscia，自2024年6月13日起担任TNF Pharmaceuticals，Inc.董事。弗里西亚先生是Kipps Capital的经理和联合创始人，Kipps Capital是一家成立于2016年的家族办公室。此前，弗里西亚曾担任多家机构投资和资产管理公司的董事总经理和投资组合经理，有几家专注于中小盘价值型股票，包括Iridian Asset Management LLC、MacKay Shields LLC、Bear Stearns Asset Management Inc.、John A. Levin & Co.，Inc.和Evergreen Investments LLC（Wachovia Corporation）。弗里西亚先生获得了佩斯大学–鲁宾商学院的学士学位。
Stephen Friscia has been Q/C Technologies, Inc. director since June 13, 2024. Mr. Friscia is the manager and co founder of Kipps Capital, a family office established in 2016. Previously, Mr. Friscia was a managing director and portfolio manager for multiple institutional investment and asset management firms, with several focused in small and mid cap value equities, including Iridian Asset Management LLC, MacKay Shields LLC, Bear Stearns Asset Management Inc., John A. Levin & Co., Inc., and Evergreen Investments LLC (Wachovia Corporation). Mr. Friscia received his B.A. from Pace University – Lubin School of Business. - Stephen Friscia，自2024年6月13日起担任TNF Pharmaceuticals，Inc.董事。弗里西亚先生是Kipps Capital的经理和联合创始人，Kipps Capital是一家成立于2016年的家族办公室。此前，弗里西亚曾担任多家机构投资和资产管理公司的董事总经理和投资组合经理，有几家专注于中小盘价值型股票，包括Iridian Asset Management LLC、MacKay Shields LLC、Bear Stearns Asset Management Inc.、John A. Levin & Co.，Inc.和Evergreen Investments LLC（Wachovia Corporation）。弗里西亚先生获得了佩斯大学–鲁宾商学院的学士学位。
- Stephen Friscia has been Q/C Technologies, Inc. director since June 13, 2024. Mr. Friscia is the manager and co founder of Kipps Capital, a family office established in 2016. Previously, Mr. Friscia was a managing director and portfolio manager for multiple institutional investment and asset management firms, with several focused in small and mid cap value equities, including Iridian Asset Management LLC, MacKay Shields LLC, Bear Stearns Asset Management Inc., John A. Levin & Co., Inc., and Evergreen Investments LLC (Wachovia Corporation). Mr. Friscia received his B.A. from Pace University – Lubin School of Business.
- Bruce Bernstein
-
Bruce Bernstein自2025年9月1日起担任Q/C Technologies，Inc.董事。Bernstein先生在证券行业拥有超过35年的经验，主要担任两只另类金融基金的高级投资组合经理以及套利策略的交易和结构设计。Bernstein先生自2006年起担任Rockmore Capital，LLC的总裁，该公司是一家直接投资和借贷基金的经理，管理的资产峰值为1.4亿美元。此前，他曾担任Omicron Capital，LP的联合总裁，这是一家位于纽约的投资公司，他于2001年加入该公司。奥密克戎资本专注于对上市小型股公司的直接投资和贷款，管理的资产峰值为2.6亿美元。在加入Omicron Capital之前，Bernstein先生曾任职于Fortis投资公司，担任该行全球证券套利业务部门的高级副总裁，专门从事股权结构性产品和股权套利业务，随后担任总裁，负责该行在美国的自营投资业务。在加入Fortis之前，Bernstein先生是野村证券国际股票衍生品组的董事，专门从事跨境税收套利、国内股权套利和结构性股权互换。伯恩斯坦先生的职业生涯始于Kidder Peabody，在那里他升至助理财务主管级别。Bernstein先生担任Xwell，Inc.的董事会成员，Xwell，Inc.是世界领先的机场水疗公司，总部位于纽约。自2016年11月14日起担任Neurotrope、Petros Pharmaceuticals，Inc.和Wrap Technologies, Inc. Technologies，Inc.的董事。Bernstein先生拥有纽约城市大学（Baruch）的工商管理学士学位。
Bruce Bernstein has over forty years of experience in the securities industry, primarily as senior portfolio manager for two alternative finance funds as well as in trading and structuring of arbitrage strategies. Mr. Bernstein has served as Managing Partner and President of Rockmore Capital, LLC since 2006, the manager of a direct investment and lending fund with peak assets under management of $150 million. Previously, he served as Co President of Omicron Capital, LP, an investment firm based in New York, which he joined in 2001. Omicron Capital focused on direct investing and lending to public small cap companies and had peak assets under management of $260 million. Prior to joining Omicron Capital, Mr. Bernstein was with Fortis Investments Inc., where he was Senior Vice President in the bank's Global Securities Arbitrage business unit, specializing in equity structured products and equity arbitrage and then President in charge of the bank's proprietary investment business in the United States. Prior to Fortis, Mr. Bernstein was Director in the Equity Derivatives Group at Nomura Securities International specializing in cross border tax arbitrage, domestic equity arbitrage and structured equity swaps. Mr. Bernstein started his career at Kidder Peabody, where he rose to the level of Assistant Treasurer. Mr. Bernstein currently serves on the boards of directors of the following public companies: XWELL, Inc. (since November 2017), TAO Synergies Corp. (since November 2016), Wrap Technologies, Inc. (since April 2023), Petros Pharmaceuticals. Inc. (since December 2020), and Q/C Technologies, Inc. (since September 2025). Mr. Bernstein holds a B.B.A. from City University of New York (Baruch). - Bruce Bernstein自2025年9月1日起担任Q/C Technologies，Inc.董事。Bernstein先生在证券行业拥有超过35年的经验，主要担任两只另类金融基金的高级投资组合经理以及套利策略的交易和结构设计。Bernstein先生自2006年起担任Rockmore Capital，LLC的总裁，该公司是一家直接投资和借贷基金的经理，管理的资产峰值为1.4亿美元。此前，他曾担任Omicron Capital，LP的联合总裁，这是一家位于纽约的投资公司，他于2001年加入该公司。奥密克戎资本专注于对上市小型股公司的直接投资和贷款，管理的资产峰值为2.6亿美元。在加入Omicron Capital之前，Bernstein先生曾任职于Fortis投资公司，担任该行全球证券套利业务部门的高级副总裁，专门从事股权结构性产品和股权套利业务，随后担任总裁，负责该行在美国的自营投资业务。在加入Fortis之前，Bernstein先生是野村证券国际股票衍生品组的董事，专门从事跨境税收套利、国内股权套利和结构性股权互换。伯恩斯坦先生的职业生涯始于Kidder Peabody，在那里他升至助理财务主管级别。Bernstein先生担任Xwell，Inc.的董事会成员，Xwell，Inc.是世界领先的机场水疗公司，总部位于纽约。自2016年11月14日起担任Neurotrope、Petros Pharmaceuticals，Inc.和Wrap Technologies, Inc. Technologies，Inc.的董事。Bernstein先生拥有纽约城市大学（Baruch）的工商管理学士学位。
- Bruce Bernstein has over forty years of experience in the securities industry, primarily as senior portfolio manager for two alternative finance funds as well as in trading and structuring of arbitrage strategies. Mr. Bernstein has served as Managing Partner and President of Rockmore Capital, LLC since 2006, the manager of a direct investment and lending fund with peak assets under management of $150 million. Previously, he served as Co President of Omicron Capital, LP, an investment firm based in New York, which he joined in 2001. Omicron Capital focused on direct investing and lending to public small cap companies and had peak assets under management of $260 million. Prior to joining Omicron Capital, Mr. Bernstein was with Fortis Investments Inc., where he was Senior Vice President in the bank's Global Securities Arbitrage business unit, specializing in equity structured products and equity arbitrage and then President in charge of the bank's proprietary investment business in the United States. Prior to Fortis, Mr. Bernstein was Director in the Equity Derivatives Group at Nomura Securities International specializing in cross border tax arbitrage, domestic equity arbitrage and structured equity swaps. Mr. Bernstein started his career at Kidder Peabody, where he rose to the level of Assistant Treasurer. Mr. Bernstein currently serves on the boards of directors of the following public companies: XWELL, Inc. (since November 2017), TAO Synergies Corp. (since November 2016), Wrap Technologies, Inc. (since April 2023), Petros Pharmaceuticals. Inc. (since December 2020), and Q/C Technologies, Inc. (since September 2025). Mr. Bernstein holds a B.B.A. from City University of New York (Baruch).
- Chelsea Voss
-
切尔西·沃斯自2026年1月16日起担任董事。自2019年9月以来，沃斯女士一直担任OpenAI的技术人员，在那里她设计大型机器学习系统，并致力于训练人工智能（“AI”）模型的数据采集工作，为GPT 4、ChatGPT、DALL·E2和Codex的推出做出了关键贡献。在加入OpenAI之前，沃斯女士于2017年9月至2019年7月在Pilot.com担任软件工程师，在那里她开发了全栈功能以改进内部会计师的工作流程，并于2016年9月至2017年8月在Chime Inc.实施了跨支付处理、欺诈预防和合规系统的功能，以支持从美国、英国和加拿大到非洲市场的大规模汇款流动。2015年11月至2016年7月，沃斯女士在哈佛医学院系统生物学系（丰塔纳实验室）担任计算系统生物学研究员，这是她在麻省理工学院教授Armando Solar Lezama主持下的M.Eng.论文的一部分。自2011年以来，沃斯女士撰写、合著或参与了许多主要与人工智能系统相关的出版物。她拥有麻省理工学院计算机科学硕士学位（2016年）和计算机科学硕士学位，辅修数学（2015年）。
Chelsea Voss has been a director since January 16, 2026. Since September 2019, Ms. Voss has served as a member of the technical staff at OpenAI where she engineers large scale machine learning systems and works on data acquisition efforts for training artificial intelligence ("AI") models, with key contributions to the launches of GPT 4, ChatGPT, DALL·E 2, and Codex. Prior to joining OpenAI, Ms. Voss worked as a software engineer at Pilot.com from September 2017 to July 2019 where she developed full stack features to improve the workflows of in house accountants and at Chime Inc. from September 2016 to August 2017 where she implemented features across payment processing, fraud prevention, and compliance systems to support large scale remittance flows from the US, UK and Canada to African markets. From November 2015 to July 2016, Ms. Voss worked as computational systems biology researcher at Harvard Medical School's Department of Systems Biology (Fontana Lab) as part of her M.Eng. thesis under Massachusetts Institute of Technology Professor Armando Solar Lezama. Since 2011, Ms. Voss has authored, co authored or contributed to numerous publications related primarily to AI systems. She holds an M.Eng. in Computer Science (2016) and an S.B. in Computer Science with a minor in Mathematics (2015) from the Massachusetts Institute of Technology. - 切尔西·沃斯自2026年1月16日起担任董事。自2019年9月以来，沃斯女士一直担任OpenAI的技术人员，在那里她设计大型机器学习系统，并致力于训练人工智能（“AI”）模型的数据采集工作，为GPT 4、ChatGPT、DALL·E2和Codex的推出做出了关键贡献。在加入OpenAI之前，沃斯女士于2017年9月至2019年7月在Pilot.com担任软件工程师，在那里她开发了全栈功能以改进内部会计师的工作流程，并于2016年9月至2017年8月在Chime Inc.实施了跨支付处理、欺诈预防和合规系统的功能，以支持从美国、英国和加拿大到非洲市场的大规模汇款流动。2015年11月至2016年7月，沃斯女士在哈佛医学院系统生物学系（丰塔纳实验室）担任计算系统生物学研究员，这是她在麻省理工学院教授Armando Solar Lezama主持下的M.Eng.论文的一部分。自2011年以来，沃斯女士撰写、合著或参与了许多主要与人工智能系统相关的出版物。她拥有麻省理工学院计算机科学硕士学位（2016年）和计算机科学硕士学位，辅修数学（2015年）。
- Chelsea Voss has been a director since January 16, 2026. Since September 2019, Ms. Voss has served as a member of the technical staff at OpenAI where she engineers large scale machine learning systems and works on data acquisition efforts for training artificial intelligence ("AI") models, with key contributions to the launches of GPT 4, ChatGPT, DALL·E 2, and Codex. Prior to joining OpenAI, Ms. Voss worked as a software engineer at Pilot.com from September 2017 to July 2019 where she developed full stack features to improve the workflows of in house accountants and at Chime Inc. from September 2016 to August 2017 where she implemented features across payment processing, fraud prevention, and compliance systems to support large scale remittance flows from the US, UK and Canada to African markets. From November 2015 to July 2016, Ms. Voss worked as computational systems biology researcher at Harvard Medical School's Department of Systems Biology (Fontana Lab) as part of her M.Eng. thesis under Massachusetts Institute of Technology Professor Armando Solar Lezama. Since 2011, Ms. Voss has authored, co authored or contributed to numerous publications related primarily to AI systems. She holds an M.Eng. in Computer Science (2016) and an S.B. in Computer Science with a minor in Mathematics (2015) from the Massachusetts Institute of Technology.
高管简历
中英对照 | 中文 | 英文- Joshua N. Silverman
Joshua N. Silverman，自2020年5月28日起担任Stablex Technologies，Inc.董事，目前担任Stablex Technologies，Inc.执行董事长兼首席执行官。在2023年12月13日被任命担任这些职位之前，Silverman先生曾担任董事会主席。在合并之前，Silverman先生自2018年合并（定义见下文）以来一直担任DropCar董事会成员。Silverman先生目前担任Parkfield Funding LLC的管理成员。Silverman先生是投资咨询公司Iroquois Capital Management，LLC（“Iroquois”）的联合创始人，之前是其负责人和管理合伙人。从2003年成立到2016年7月，Silverman先生担任Iroquois的联席首席投资官。在Iroquois任职期间，他设计并执行了复杂的交易，构建和谈判对公共和私营公司的投资，并经常被这类公司要求解决与公司结构、现金流和管理相关的低效率问题。2000年至2003年，Silverman先生担任商业银行Vertical Ventures，LLC的联席首席投资官。在组建Iroquois之前，Silverman先生是专门从事并购的精品咨询公司Joele Frank的董事。此前，Silverman曾担任美国总统助理新闻秘书。Silverman先生目前担任MYMD Pharmaceuticals，Inc.（NASDAQ：MYMD）、Pharmacyte，Inc.（NASDAQ：PMCB）、Synaptogenix, Inc.TERM3（NASDAQ：SNPX）和Petros Pharmaceutical，Inc.（NASDAQ：PTPI）的董事，这些公司均为上市公司。他此前于2014年7月至2016年8月担任国家控股公司董事，并于2016年8月至2018年10月担任Marker Therapeutics公司董事。Silverman先生于1992年获得了Lehigh大学的学士学位。
Joshua N. Silverman has served as a director of the Company since August 2022 and as Pharmacyte Biotech, Inc.'s Chief Executive Officer, President and Chairman of the Board since October 2022. Mr. Silverman has served as the managing member of Parkfield Funding LLC since August 2016. Mr. Silverman co founded Iroquois Capital Management, LLC ("Iroquois"), an investment advisory firm, in 2003 and served as its principal, managing partner and co chief investment officer until July 2016. While at Iroquois, he designed and executed complex transactions, structuring and negotiating investments in both public and private companies and has often been called upon by the companies solve inefficiencies as they relate to corporate structure, cash flow, and management. From 2000 to 2003, Mr. Silverman served as co chief investment officer of Vertical Ventures, LLC, a merchant bank. Prior to forming Iroquois, Mr. Silverman was a director of Joele Frank, a boutique consulting firm specializing in mergers and acquisitions. Previously, Mr. Silverman served as assistant press secretary to the president of the U.S. Mr. Silverman currently serves as an Executive Chairman of Fabric AI, Inc., (Nasdaq: FABC), Q/C Technologies, Inc. (Nasdaq: QCLS), TAO Synergies Inc. (Nasdaq: TAOX) and Petros Pharmaceutical, Inc. (OTC: PTPI). He previously served as a director of Protagenic Therapeutics, Inc. (Nasdaq: PTIX) from 2016 to 2022. Mr. Silverman received his B.A. from Lehigh University in 1992.- Joshua N. Silverman，自2020年5月28日起担任Stablex Technologies，Inc.董事，目前担任Stablex Technologies，Inc.执行董事长兼首席执行官。在2023年12月13日被任命担任这些职位之前，Silverman先生曾担任董事会主席。在合并之前，Silverman先生自2018年合并（定义见下文）以来一直担任DropCar董事会成员。Silverman先生目前担任Parkfield Funding LLC的管理成员。Silverman先生是投资咨询公司Iroquois Capital Management，LLC（“Iroquois”）的联合创始人，之前是其负责人和管理合伙人。从2003年成立到2016年7月，Silverman先生担任Iroquois的联席首席投资官。在Iroquois任职期间，他设计并执行了复杂的交易，构建和谈判对公共和私营公司的投资，并经常被这类公司要求解决与公司结构、现金流和管理相关的低效率问题。2000年至2003年，Silverman先生担任商业银行Vertical Ventures，LLC的联席首席投资官。在组建Iroquois之前，Silverman先生是专门从事并购的精品咨询公司Joele Frank的董事。此前，Silverman曾担任美国总统助理新闻秘书。Silverman先生目前担任MYMD Pharmaceuticals，Inc.（NASDAQ：MYMD）、Pharmacyte，Inc.（NASDAQ：PMCB）、Synaptogenix, Inc.TERM3（NASDAQ：SNPX）和Petros Pharmaceutical，Inc.（NASDAQ：PTPI）的董事，这些公司均为上市公司。他此前于2014年7月至2016年8月担任国家控股公司董事，并于2016年8月至2018年10月担任Marker Therapeutics公司董事。Silverman先生于1992年获得了Lehigh大学的学士学位。
- Joshua N. Silverman has served as a director of the Company since August 2022 and as Pharmacyte Biotech, Inc.'s Chief Executive Officer, President and Chairman of the Board since October 2022. Mr. Silverman has served as the managing member of Parkfield Funding LLC since August 2016. Mr. Silverman co founded Iroquois Capital Management, LLC ("Iroquois"), an investment advisory firm, in 2003 and served as its principal, managing partner and co chief investment officer until July 2016. While at Iroquois, he designed and executed complex transactions, structuring and negotiating investments in both public and private companies and has often been called upon by the companies solve inefficiencies as they relate to corporate structure, cash flow, and management. From 2000 to 2003, Mr. Silverman served as co chief investment officer of Vertical Ventures, LLC, a merchant bank. Prior to forming Iroquois, Mr. Silverman was a director of Joele Frank, a boutique consulting firm specializing in mergers and acquisitions. Previously, Mr. Silverman served as assistant press secretary to the president of the U.S. Mr. Silverman currently serves as an Executive Chairman of Fabric AI, Inc., (Nasdaq: FABC), Q/C Technologies, Inc. (Nasdaq: QCLS), TAO Synergies Inc. (Nasdaq: TAOX) and Petros Pharmaceutical, Inc. (OTC: PTPI). He previously served as a director of Protagenic Therapeutics, Inc. (Nasdaq: PTIX) from 2016 to 2022. Mr. Silverman received his B.A. from Lehigh University in 1992.
- Ian Rhodes
Ian Rhodes自2021年2月1日起担任我们的临时首席财务官。罗兹先生于2021年1月加入Brio Financial Group“；Brio”；。从2020年3月至2020年12月，罗兹先生担任Roadway Moving and Storage的临时首席财务官。从2018年11月至2019年7月，他担任Greyston Bakery and Foundation的临时首席财务官。从2016年12月至2018年9月，罗兹先生担任Glyeco，Inc.的总裁，首席执行官兼董事，并于2016年2月至2016年12月担任Glyeco，Inc.的首席财务官。从2014年5月到2016年1月，他担任Calmare Therapeutics的首席财务官。
Ian Rhodes has been Q/C Technologies, Inc. Interim Chief Financial Officer since February 1, 2021. Since August 2024, Mr. Rhodes has been the Chief Financial Officer of Renatus Tactical Acquisition Corp I. Mr. Rhodes joined Brio Financial Group ("Brio") in January 2021. From March 2020 to December 2020, Mr. Rhodes has served as the Chief Financial Officer of Apogee Acquisition Corp. since November 2025. Mr. Rhodes served as the Interim Chief Financial Officer of Roadway Moving and Storage. From November 2018 to July 2019, he served as Interim CFO of Greyston Bakery and Foundation. From December 2016 to September 2018, Mr. Rhodes served as President, Chief Executive Officer and Director of GlyEco, Inc., and served as Chief Financial Officer of GlyEco, Inc. from February 2016 to December 2016. From May 2014 to January 2016, he served as Chief Financial Officer of Calmare Therapeutics. Mr. Rhodes began his career at PricewaterhouseCoopers, where he worked for 15 years. Mr. Rhodes holds a Bachelor of Science degree in Business Administration with a concentration in Accounting from Seton Hall University.- Ian Rhodes自2021年2月1日起担任我们的临时首席财务官。罗兹先生于2021年1月加入Brio Financial Group“；Brio”；。从2020年3月至2020年12月，罗兹先生担任Roadway Moving and Storage的临时首席财务官。从2018年11月至2019年7月，他担任Greyston Bakery and Foundation的临时首席财务官。从2016年12月至2018年9月，罗兹先生担任Glyeco，Inc.的总裁，首席执行官兼董事，并于2016年2月至2016年12月担任Glyeco，Inc.的首席财务官。从2014年5月到2016年1月，他担任Calmare Therapeutics的首席财务官。
- Ian Rhodes has been Q/C Technologies, Inc. Interim Chief Financial Officer since February 1, 2021. Since August 2024, Mr. Rhodes has been the Chief Financial Officer of Renatus Tactical Acquisition Corp I. Mr. Rhodes joined Brio Financial Group ("Brio") in January 2021. From March 2020 to December 2020, Mr. Rhodes has served as the Chief Financial Officer of Apogee Acquisition Corp. since November 2025. Mr. Rhodes served as the Interim Chief Financial Officer of Roadway Moving and Storage. From November 2018 to July 2019, he served as Interim CFO of Greyston Bakery and Foundation. From December 2016 to September 2018, Mr. Rhodes served as President, Chief Executive Officer and Director of GlyEco, Inc., and served as Chief Financial Officer of GlyEco, Inc. from February 2016 to December 2016. From May 2014 to January 2016, he served as Chief Financial Officer of Calmare Therapeutics. Mr. Rhodes began his career at PricewaterhouseCoopers, where he worked for 15 years. Mr. Rhodes holds a Bachelor of Science degree in Business Administration with a concentration in Accounting from Seton Hall University.
- Mitchell Glass
Mitchell Glass，自2024年4月8日起担任TNF Pharmaceuticals，Inc.董事，目前担任TNF Pharmaceuticals，Inc.总裁兼首席医疗官，该职位自2024年6月13日起担任。Glass博士是生命科学行业35年的资深人士。他的经历范围很广，从十大制药公司的高级职位到投资和管理初创企业和生物技术。在宾夕法尼亚大学从事了七年的研究、教学和患者护理工作后，Glass博士于1988年加入ICI Pharmaceuticals。他成立了肺部治疗小组，并领导了抗白三烯ACCOLATE 的开发和提交。从1995年到1996年，Dr. Glass担任SmithKline Beecham的副总裁兼董事，负责心血管、呼吸、肾脏和代谢药物的开发和商业化，包括提交COREG 的NDA/MAA。1998年至2003年，Glass博士担任AtheroGenics，Inc.（AGIX）首席医疗官兼临床开发和监管事务副总裁。他领导了AGI 1067从IND到3期的产品开发，是首次公开发行团队成员。Glass博士加入AQUMEN Biopharmaceuticals KK和NA，担任AQUMEN NA首席执行官和董事。自2008年以来，Glass博士一直担任OrphageniX Inc.（基因编辑）和AVATAR Biotechnologies（生物仿制药）的董事，现在是Invion LTD的研发执行副总裁和首席医疗官。Glass博士毕业于芝加哥大学，获得了内科、肺部和重症医学的董事会认证。
Mitchell Glass has been Q/C Technologies, Inc. director since April 8, 2024, and currently serves as Q/C Technologies, Inc. Chief Medical Officer, a position he has held since June 13, 2024. Dr. Glass previously served as President of the Company from June 13, 2024 until September 1, 2025. Dr. Glass is presently Chief Executive Officer of Chronic Airway Therapeutics, Chairman and Chief Executive Officer of ACCOLADE Pharma LLC and a principal at Broom Street Associates. Previously, Dr. Glass was director of pulmonary therapeutics at ICI/Zeneca and responsible world wide for the development of zafirlukast ("Accolate), the first successful antileukotriene for the treatment of asthma. Dr. Glass also served as Vice President at SmithKline Beecham beginning March, 1995, where he also held executive roles in the development of carvedilol (COREG) for heart failure, eprosartan (TEVETEN) for hypertension and led the worldwide portfolio development in cardiovascular, respiratory, renal and metabolic diseases and disorders. At Athrogenix, Dr. Glass led the development of AGI1067 to a successful end of phase 2 meeting with the FDA. After 2 years as the CSO of the University City Science Center in Philadelphia between 2005 and 2006, which included responsibility for 54 early stage companies, Dr. Glass joined Aqumen Pharma KK ("Aqumen Pharma") in 2006 as Director Aqumen KK. Dr. Glass also served as Chief Executive Officer and Chief Medical Officer of Aqumen Pharma's U.S. subsidiary was responsible for the ophthalmic portfolio, the lead compound of which was successfully developed and marketed in the U.S. and served in such roles until 2011. Previously, Dr. Glass served as the Chief Medical Officer and Director at Invion Plc. (ASX IVN) ("Invion") beginning 2011 until 2019 and led the de merger of Invion into Chronic Airway Therapeutics, the lead compound of which, nadolol, executed a positive proof of concept study in smokers with bronchitis. Dr. Glass graduated from the University of Chicago and is board certified in internal medicine, pulmonary and critical care medicine.- Mitchell Glass，自2024年4月8日起担任TNF Pharmaceuticals，Inc.董事，目前担任TNF Pharmaceuticals，Inc.总裁兼首席医疗官，该职位自2024年6月13日起担任。Glass博士是生命科学行业35年的资深人士。他的经历范围很广，从十大制药公司的高级职位到投资和管理初创企业和生物技术。在宾夕法尼亚大学从事了七年的研究、教学和患者护理工作后，Glass博士于1988年加入ICI Pharmaceuticals。他成立了肺部治疗小组，并领导了抗白三烯ACCOLATE 的开发和提交。从1995年到1996年，Dr. Glass担任SmithKline Beecham的副总裁兼董事，负责心血管、呼吸、肾脏和代谢药物的开发和商业化，包括提交COREG 的NDA/MAA。1998年至2003年，Glass博士担任AtheroGenics，Inc.（AGIX）首席医疗官兼临床开发和监管事务副总裁。他领导了AGI 1067从IND到3期的产品开发，是首次公开发行团队成员。Glass博士加入AQUMEN Biopharmaceuticals KK和NA，担任AQUMEN NA首席执行官和董事。自2008年以来，Glass博士一直担任OrphageniX Inc.（基因编辑）和AVATAR Biotechnologies（生物仿制药）的董事，现在是Invion LTD的研发执行副总裁和首席医疗官。Glass博士毕业于芝加哥大学，获得了内科、肺部和重症医学的董事会认证。
- Mitchell Glass has been Q/C Technologies, Inc. director since April 8, 2024, and currently serves as Q/C Technologies, Inc. Chief Medical Officer, a position he has held since June 13, 2024. Dr. Glass previously served as President of the Company from June 13, 2024 until September 1, 2025. Dr. Glass is presently Chief Executive Officer of Chronic Airway Therapeutics, Chairman and Chief Executive Officer of ACCOLADE Pharma LLC and a principal at Broom Street Associates. Previously, Dr. Glass was director of pulmonary therapeutics at ICI/Zeneca and responsible world wide for the development of zafirlukast ("Accolate), the first successful antileukotriene for the treatment of asthma. Dr. Glass also served as Vice President at SmithKline Beecham beginning March, 1995, where he also held executive roles in the development of carvedilol (COREG) for heart failure, eprosartan (TEVETEN) for hypertension and led the worldwide portfolio development in cardiovascular, respiratory, renal and metabolic diseases and disorders. At Athrogenix, Dr. Glass led the development of AGI1067 to a successful end of phase 2 meeting with the FDA. After 2 years as the CSO of the University City Science Center in Philadelphia between 2005 and 2006, which included responsibility for 54 early stage companies, Dr. Glass joined Aqumen Pharma KK ("Aqumen Pharma") in 2006 as Director Aqumen KK. Dr. Glass also served as Chief Executive Officer and Chief Medical Officer of Aqumen Pharma's U.S. subsidiary was responsible for the ophthalmic portfolio, the lead compound of which was successfully developed and marketed in the U.S. and served in such roles until 2011. Previously, Dr. Glass served as the Chief Medical Officer and Director at Invion Plc. (ASX IVN) ("Invion") beginning 2011 until 2019 and led the de merger of Invion into Chronic Airway Therapeutics, the lead compound of which, nadolol, executed a positive proof of concept study in smokers with bronchitis. Dr. Glass graduated from the University of Chicago and is board certified in internal medicine, pulmonary and critical care medicine.